Combining TMS and Ketamine for Treatment-Resistant Depression: Clinical Rationale, Current Evidence, and Practical Guidance.
Focus (Am Psychiatr Publ) July 8, 2026 DOI: 10.1176/appi.focus.20260014 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Depression Esketamine Ketamine |
| Key findings | Argues that combining TMS and ketamine for treatment-resistant depression is clinically rational and shows preliminary promise, but current evidence is limited and more rigorous research is needed to confirm efficacy and guide clinical use. |
Abstract
Combining TMS and Ketamine for Treatment-Resistant Depression: Clinical Rationale, Current Evidence, and Practical Guidance.
Comparable studies
Other narrative reviews on ketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Ketamine: a paradigm shift for depression research and treatment | 2019 | Review | |
| Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective | 2019 | Review | |
| Ketamine: A tale of two enantiomers | 2020 | Review | |
| Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor | 2021 | Review |